Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02523339
Other study ID # UI-CRVO-2015
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 2014
Est. completion date November 3, 2020

Study information

Verified date February 2021
Source University of Iceland
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of the study is to test if oxygen saturation in retinal vessels is correlated with clinical parameters, such as visual acuity, central retinal thickness and presence of neovascularization. Retinal oximetry is performed with fundus camera based oximeters. The study will not entail change in treatment of the disease.


Recruitment information / eligibility

Status Completed
Enrollment 117
Est. completion date November 3, 2020
Est. primary completion date June 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Suspected central retinal vein occlusion. - Informed consent for participation. - No treatment before the first oximetry measurement. Exclusion Criteria: - History of other retinal disease. Glaucoma and diabetes without retinopathy are not exclusion criteria but should be registered. - History of cardiovascular or respiratory diseases that can be expected to influence systemic or retinal oxygen saturation. Examples: Known COPD or carotid stenosis. Subjects with high blood pressure will not be excluded but blood pressure should be registered. - Poor quality images will be excluded based on the images themselves. Therefore, grading of cataract or other media opacities is not strictly necessary for the purpose of the study.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Austria Department of Clinical Pharmacology, Medical University of Vienna Vienna
Czechia Department of Ophthalmology, University Hospital and Faculty of Medicine and Dentistry, Palacky University Olomouc Olomouc
Denmark Aarhus University. Department of Clinical Medicine - The Department of Ophthalmology Aarhus
Germany University Hospital Jena Jena
Iceland University of Iceland / Landspitali, Dept. of Ophthalmology Reykjavik
Switzerland Eye Clinic of the University Hospital Basel Basel Basel-Stadt
Switzerland Clinical Research Center Memorial A. de Rothschild Geneva
United Kingdom Aston University School of Life and Health Sciences Birmingham

Sponsors (9)

Lead Sponsor Collaborator
University of Iceland Aston University, Clinical Research Center Memorial A. de Rothschild, Medical University of Vienna, Palacky University, University Hospital, Basel, Switzerland, University of Aarhus, University of Jena, University of Toyama

Countries where clinical trial is conducted

Austria,  Czechia,  Denmark,  Germany,  Iceland,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Retinal vessel oxygen saturation 12 months
Primary Visual acuity 12 months
Primary Central retinal thickness 12 months
Primary Presence or absence of ocular neovascularisation As determined by gonioscopic examination 12 months
Secondary Retinal vessel oxygen saturation Baseline
Secondary Visual acuity Baseline
Secondary Central retinal thickness Baseline
Secondary Presence or absence of ocular neovascularisation As determined by gonioscopic examination Baseline
Secondary Retinal vessel oxygen saturation 3 months
Secondary Visual acuity 3 months
Secondary Central retinal thickness 3 months
Secondary Presence or absence of ocular neovascularisation As determined by gonioscopic examination 3 months
Secondary Retinal vessel oxygen saturation 6 months
Secondary Visual acuity 6 months
Secondary Central retinal thickness 6 months
Secondary Presence or absence of ocular neovascularisation As determined by gonioscopic examination 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT06262737 - Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
Completed NCT04592419 - A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) Phase 3
Recruiting NCT05133791 - NIR Fluorescence Molecular Imaging of ANXV-800CW in RVO Patients Phase 1
Withdrawn NCT04011358 - Retinal Vein Occlusion and Obstructive Sleep Apnea: A Case Control Study N/A
Completed NCT02898480 - Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning N/A
Recruiting NCT01581151 - Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion N/A
Completed NCT01428388 - Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion N/A
Completed NCT00970957 - Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion Phase 3
Recruiting NCT04075695 - Ultra-wide-field Fluorescein Angiography in Patients With Retinal Vein Occlusion
Recruiting NCT03525132 - Study of the Retinal Vascularization by Laser Doppler Velocimetry Coupled With an Adaptive Optics Camera ( AO-LDV) N/A
Recruiting NCT03762226 - Influence of Systemic Parameters in Diabetic Macular Edema - LIPSIA Study
Recruiting NCT02257333 - Retinal Thrombosis and Atherosclerosis
Recruiting NCT04140448 - Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion
Active, not recruiting NCT05003258 - Functional and Anatomical Outcomes of Dexamethasone Intra-vitreal Implant in Patients With Resistant Macular Edema Secondary to Retinal Vein Occlusion After Intravitreal Anti-VEGF Injection N/A
Terminated NCT04707625 - Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment Phase 4
Recruiting NCT04142164 - Computer-based Tutorial and Automated Speech Recognition for Intravitreal Drug Injections N/A
Active, not recruiting NCT01449682 - Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections. Phase 3
Completed NCT01568021 - Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO) N/A
Terminated NCT01225146 - Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) Phase 1
Completed NCT01012973 - Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) Phase 3